Trials / Recruiting
RecruitingNCT06146660
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 600 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational post-marketing surveillance study is to assess the real-world safety of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult participants in Korea. Participants who will receive at least 1 dose of mavacamten will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavacamten | According to approved product label |
Timeline
- Start date
- 2024-07-24
- Primary completion
- 2026-11-30
- Completion
- 2026-11-30
- First posted
- 2023-11-27
- Last updated
- 2024-11-06
Locations
2 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06146660. Inclusion in this directory is not an endorsement.